Clinical trials
catalyst calendar across sponsors →Studies where AORT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 2 observational · 3 with posted results
Held by 11 tracked-famous managers (CITADEL ADVISORS LLC, Qube Research & Technologies Ltd, D. E. Shaw & Co., Inc., TWO SIGMA INVESTMENTS, LP, Balyasny Asset Management L.P., +6 more) · FINRA short interest 4.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 2 sells · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Mitral Valve Repair With the Chord-X System: A Long Term EvaluationNCT07413926observationalRecurrent Mitral Regurgitation | — | Not yet recruiting | Device: Chord-X system implant | Mitral Regurgitation (MR) | 110 | Mar 2034 | ≤ 2,781 d | 2026-02-20 |
| Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSANCT07089576Composite Rate of Patients Free From ≥1 Major Adverse EventNon-randomized · Open-label · Treatment | Not applicable | Recruiting | Device: Arcevo™ LSA Hybrid Stent Graft System | Aortic Arch Aneurysm, Aortic Arch Dissection, Chronic Aortic Dissection, Acute Aortic Dissection | 132 | Apr 2028 | ≤ 620 d | 2026-07-10 |
| PERSEVERE- A Trial to Evaluate AMDS in Acute DeBakey Type I DissectionNCT05174767Primary Endpoint to Assess Incidence of Major Adverse EventsOpen-label · Treatment | Not applicable | Active, not recruiting | Device: AMDS | Acute Aortic Dissection | 115 | 2023-12-11actual | — | 2025-01-15 |
| PROACT Xa - A Trial to Determine if Participants With an On-X Aortic Valve Can be Maintained Safely on ApixabanNCT04142658results2024-03-20Composite of Valve Thrombosis and Valve-related ThromboembolismRandomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Safety | Drug: Apixaban 5 MG, Apixaban 2.5 MG, Warfarin · Device: On-X Aortic Mechanical Valve | Aortic Valve Disease, Aortic Valve Stenosis, Aortic Valve Failure | 863 | 2022-12-12actual | — | 2024-03-20 |
| Retrospective Evaluation of Photo-oxidized Decellularized Bovine Pericardium in Cardiac Repair or Reconstruction SurgeryNCT05314868observationalOverall survival | — | Terminatedsponsor's stated reason: Sponsor declined to continue funding the study. | Device: PhotoFix | Congenital Heart Disease, Cardiac Anomaly | 10 | 2022-11-30actual | — | 2023-01-13 |
| Post-market, Prospective Evaluation of PHOTO-oxidized Bovine Pericardium in Vascular SurgeryNCT03669042results2024-10-08Incidence of Central Neurologic EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: PhotoFix | Vascular Diseases, Peripheral Arterial Disease, Hemodialysis Access Failure (Disorder), Carotid Artery Diseases, Abdominal Aortic Aneurism | 94 | 2020-07-10actual | — | 2024-10-08 |
| Prospective, Multicenter, Multidisciplinary, Controlled Clinical Investigation Evaluating the Safety and Efficacy of PerClot® Polysaccharide Hemostatic SystemNCT02359994results2022-03-17Number of Participants With Achievement of Hemostasis at 7 MinutesRandomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: PerClot Polysaccharide Hemostatic System, Arista AH | Blood Loss, Surgical | 324 | 2019-01-11actual | — | 2022-03-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19